Y Intercept Hong Kong Ltd Purchases Shares of 85,227 Immunome, Inc. $IMNM

Y Intercept Hong Kong Ltd purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 85,227 shares of the company’s stock, valued at approximately $793,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. MetLife Investment Management LLC boosted its holdings in shares of Immunome by 19.1% in the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after acquiring an additional 6,792 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Immunome by 55.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after acquiring an additional 275,000 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of Immunome in the 1st quarter valued at approximately $1,776,000. Charles Schwab Investment Management Inc. lifted its position in shares of Immunome by 34.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock valued at $4,135,000 after acquiring an additional 157,135 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Immunome by 66.2% in the 1st quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock valued at $126,000 after acquiring an additional 7,476 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating and issued a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 target price for the company. Wedbush restated an “outperform” rating and set a $21.00 price target on shares of Immunome in a report on Thursday, September 18th. Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price on the stock. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.20.

Immunome Trading Down 0.4%

Shares of NASDAQ IMNM opened at $15.35 on Thursday. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $17.87. The company has a market cap of $1.34 billion, a PE ratio of -4.98 and a beta of 1.96. The company has a 50-day moving average of $12.60 and a two-hundred day moving average of $10.39.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.02. The business had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. As a group, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.